Camrelizumab vs Pembrolizumab berahyaluronidase alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Camrelizumab
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
NCT03134872 · Phase 3 · completed
CameL was a randomized, open-label Phase 3 trial in 419 patients with untreated non-squamous non-small-cell lung cancer without EGFR or ALK alterations, which compared camrelizumab plus carboplatin and pemetrexed with chemotherapy alone. It had two primary endpoints: progression-free survival in all patients and in PD-L1-positive patients. At the interim analysis, progression-free survival in all patients was significantly longer with camrelizumab (11.3 vs 8.3 months; hazard ratio 0.60). The paper reports confirmatory testing only for all patients, and no published result tests the PD-L1-positive primary, so the result is shown as unclear. The figures come from the peer-reviewed paper (Zhou et al., Lancet Respir Med 2021).
Next expected readout: December 2027 · NCT07016126 (registry estimate)
Reported efficacy
Progression-Free Survival in the intent-to-treat (ITT) population (up to 24 months); Progression-Free Survival in the PD-L1-selected population (up to 24 months): Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. (unclear)
Result source: NCT03134872
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT05722015 · Phase 3 · active, not recruiting
Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.
Next expected readout: December 2029 · NCT07190248 (registry estimate)
Reported efficacy
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)
Result source: NCT05722015
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Camrelizumab | Pembrolizumab berahyaluronidase alfa |
|---|---|---|
| PFS, median | 11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872 | —Trial running · NCT05722015 |
| OS, median | —Not posted · NCT03134872 | —Trial running · NCT05722015 |
| ORR | 16.7%bNCT03083041 | 64.3% vs 18.2%vs PembrolizumabNCT06212752 |
| Duration of response, median | —Not posted · NCT03134872 | —Trial running · NCT05722015 |
PFS, median
- Camrelizumab
- 11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
OS, median
- Camrelizumab
- —Not posted · NCT03134872
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
ORR
- Camrelizumab
- 16.7%bNCT03083041
- Pembrolizumab berahyaluronidase alfa
- 64.3% vs 18.2%vs PembrolizumabNCT06212752
Duration of response, median
- Camrelizumab
- —Not posted · NCT03134872
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Camrelizumab: 3 of 4 rows · Pembrolizumab berahyaluronidase alfa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Camrelizumab | Pembrolizumab berahyaluronidase alfa |
|---|---|---|
| Dropout rate | 91.7%375 mga NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | n/a: no completion milestoneb NCT05722015 · Phase 3 · combination show 1 more resultn/a: no completion milestone NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | —375 mga NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | —b NCT05722015 · Phase 3 · combination show 1 more result— NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 58.3%375 mga NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result56.6%250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 39%b NCT05722015 · Phase 3 · combination show 1 more result42.9% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | 375 mga rash 91.7% hypertension 83.3% decreased appetite 75% NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result250 mg hypertension 63.6% proteinuria 63.1% aspartate aminotransferase increased 53.5% NCT03083041 · Phase 2 · registry result, not featured evidence · combination | show 1 more resultneutropenia 46.4% anaemia 42.9% constipation 39.3% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Camrelizumab
Pembrolizumab berahyaluronidase alfa
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camrelizumab's landscape · Pembrolizumab berahyaluronidase alfa's landscape